Free Trial
NASDAQ:RNXT

RenovoRx (RNXT) Stock Price, News & Analysis

RenovoRx logo
$1.19 -0.04 (-3.25%)
Closing price 05/23/2025 04:00 PM Eastern
Extended Trading
$1.25 +0.06 (+5.46%)
As of 05/23/2025 07:44 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About RenovoRx Stock (NASDAQ:RNXT)

Key Stats

Today's Range
$1.17
$1.24
50-Day Range
$0.77
$1.24
52-Week Range
$0.75
$1.69
Volume
98,022 shs
Average Volume
85,755 shs
Market Capitalization
$43.52 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$7.00
Consensus Rating
Buy

Company Overview

RenovoRx, Inc., a clinical-stage biopharmaceutical company, focuses on developing proprietary targeted combination therapies to improve therapeutic outcomes for cancer patients undergoing treatment. Its lead product candidate is RenovoGem, an oncology drug-device combination product, consisting of intra-arterial gemcitabine and RenovoCath that is in Phase III clinical trials for the locally advanced pancreatic cancer. The company has a research collaboration with Imugene Limited to deliver oncolytic virus therapy for the treatment of difficult-to-access tumors. RenovoRx, Inc. was founded in 2009 and is headquartered in Los Altos, California.

RenovoRx Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
48th Percentile Overall Score

RNXT MarketRank™: 

RenovoRx scored higher than 48% of companies evaluated by MarketBeat, and ranked 539th out of 919 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    RenovoRx has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    RenovoRx has only been the subject of 2 research reports in the past 90 days.

  • Read more about RenovoRx's stock forecast and price target.
  • Earnings Growth

    Earnings for RenovoRx are expected to decrease in the coming year, from ($0.40) to ($0.46) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of RenovoRx is -2.09, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of RenovoRx is -2.09, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Read more about RenovoRx's valuation and earnings.
  • Percentage of Shares Shorted

    0.72% of the float of RenovoRx has been sold short.
  • Short Interest Ratio / Days to Cover

    RenovoRx has a short interest ratio ("days to cover") of 1.8, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in RenovoRx has recently decreased by 15.18%, indicating that investor sentiment is improving significantly.
  • Dividend Yield

    RenovoRx does not currently pay a dividend.

  • Dividend Growth

    RenovoRx does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    0.72% of the float of RenovoRx has been sold short.
  • Short Interest Ratio / Days to Cover

    RenovoRx has a short interest ratio ("days to cover") of 1.8, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in RenovoRx has recently decreased by 15.18%, indicating that investor sentiment is improving significantly.
  • News Sentiment

    RenovoRx has a news sentiment score of -0.38. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.74 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 7 news articles for RenovoRx this week, compared to 1 article on an average week.
  • Search Interest

    4 people have searched for RNXT on MarketBeat in the last 30 days. This is an increase of 100% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, RenovoRx insiders have bought more of their company's stock than they have sold. Specifically, they have bought $90,218.00 in company stock and sold $0.00 in company stock.

  • Percentage Held by Insiders

    Only 9.13% of the stock of RenovoRx is held by insiders.

  • Percentage Held by Institutions

    Only 3.10% of the stock of RenovoRx is held by institutions.

  • Read more about RenovoRx's insider trading history.
Receive RNXT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for RenovoRx and its competitors with MarketBeat's FREE daily newsletter.

RNXT Stock News Headlines

Q2 Earnings Forecast for RenovoRx Issued By HC Wainwright
RenovoRx's (RNXT) "Buy" Rating Reaffirmed at HC Wainwright
Trump Predicts Dollar Downfall
READ THIS VERY CAREFULLY: If you have $100,000 or more saved for retirement, this may make you VERY angry... This is what President Trump said: "Our currency is crashing and will soon no longer be the world standard, which will be our greatest defeat, frankly, in 200 years." Why Would He Say This?
See More Headlines

RNXT Stock Analysis - Frequently Asked Questions

RenovoRx's stock was trading at $1.29 at the beginning of the year. Since then, RNXT shares have decreased by 7.8% and is now trading at $1.19.
View the best growth stocks for 2025 here
.

RenovoRx, Inc. (NASDAQ:RNXT) issued its quarterly earnings results on Thursday, May, 15th. The company reported ($0.08) earnings per share for the quarter, meeting analysts' consensus estimates of ($0.08). The company had revenue of $0.20 million for the quarter, compared to the consensus estimate of $0.23 million.
Read the conference call transcript
.

RenovoRx (RNXT) raised $18 million in an IPO on Thursday, August 26th 2021. The company issued 1,800,000 shares at $9.00-$11.00 per share. Roth Capital Partners and Maxim Group LLC acted as the underwriters for the IPO.

Top institutional investors of RenovoRx include AIGH Capital Management LLC (9.49%), AWM Investment Company Inc. (6.25%), Alyeska Investment Group L.P. (1.88%) and ADAR1 Capital Management LLC (1.31%). Insiders that own company stock include Ramtin Agah, Shaun Bagai, Laurence Marton, Ron Kocak and Angela Nelms.
View institutional ownership trends
.

Shares of RNXT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that RenovoRx investors own include Zomedica (ZOM), Jumia Technologies (JMIA), Nano Dimension (NNDM), AST SpaceMobile (ASTS), Bakkt (BKKT), NIO (NIO) and Phunware (PHUN).

Company Calendar

Last Earnings
5/15/2025
Today
5/24/2025
Next Earnings (Estimated)
8/12/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:RNXT
Employees
6
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$7.00
High Stock Price Target
$11.00
Low Stock Price Target
$3.00
Potential Upside/Downside
+488.2%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
2 Analysts

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-10,230,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$240,000.00
Price / Cash Flow
N/A
Book Value
($0.28) per share
Price / Book
-4.25

Miscellaneous

Free Float
22,297,000
Market Cap
$43.52 million
Optionable
Not Optionable
Beta
1.12
7 Stocks to Buy And Hold Forever Cover

Enter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

This page (NASDAQ:RNXT) was last updated on 5/24/2025 by MarketBeat.com Staff
From Our Partners